Published in Cancer Weekly, September 7th, 2004
In the multi-center study, an investigational molecular test called uPM3 gave a correct positive or negative result for the presence of prostate cancer 81% of the time. The uPM3 test detects the presence of a new prostate cancer gene marker called PCA3 in urine. In contrast, traditional prostate cancer detection by measuring total prostate specific antigen levels, or tPSA, had an overall accuracy of 43% or 47% in the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.